Morgens Waterfall Vintiadis & Co’s ADMA Biologics ADMA Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-600,000	Closed	-$2.4M	–	31
2019 Q4	$2.4M	Buy	600,000 +50,000	+9%	+$218K	1.63%	27
2019 Q3	$2.45M	Hold	550,000	–	–	1.88%	26
2019 Q2	$2.13M	Sell	550,000 -25,000	-4%	-$110K	1.47%	29
2019 Q1	$2.18M	Buy	575,000 +175,000	+44%	+$619K	1.56%	28
2018 Q4	$956K	Buy	400,000 +25,000	+7%	+$124K	0.85%	39
2018 Q3	$2.33M	Hold	375,000	–	–	1.52%	28
2018 Q2	$1.69M	Buy	375,000 +75,000	+25%	+$374K	1.2%	27
2018 Q1	$1.38M	Sell	300,000 -200,000	-40%	-$795K	1.05%	29
2017 Q4	$1.6M	Buy	+500,000	New	+$1.4M	1.26%	27

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's ADMA Position: Q1 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of ADMA Biologics (ADMA) in Q1 2020, closing a stake of 600,000 shares — an estimated $2.4M sold.

Morgens Waterfall Vintiadis & Co first reported a position in ADMA in Q4 2017 and held it in 9 quarters. The position peaked at $2.45M in Q3 2019. 91 funds tracked by Wall St. Rank hold ADMA as of Q1 2020.

Morgens Waterfall Vintiadis & Co reported no remaining ADMA Biologics position as of Q1 2020 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 600,000 ADMA Biologics shares in Q1 2020, an estimated $2.4M.
Morgens Waterfall Vintiadis & Co first reported a position in ADMA Biologics in Q4 2017 and held it in 9 quarters.
Morgens Waterfall Vintiadis & Co's ADMA Biologics position peaked at $2.45M in Q3 2019.
91 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2020, filed 15 May 2020.